Search hospitals > South Carolina > Charleston
Medical University of South Carolina
Claim this profileCharleston, South Carolina 29401
Global Leader in Cancer
Global Leader in Fibrosis
Conducts research for Leukemia
Conducts research for Stroke
Conducts research for Tumors
2284 reported clinical trials
178 medical researchers
Summary
Medical University of South Carolina is a medical facility located in Charleston, South Carolina. This center is recognized for care of Cancer, Fibrosis, Leukemia, Stroke, Tumors and other specialties. Medical University of South Carolina is involved with conducting 2,284 clinical trials across 1,783 conditions. There are 178 research doctors associated with this hospital, such as Jacqueline M. Kraveka, Gregory Cote, MD, Michael Gold, MD, and Mariam Alexander.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Fibrosis
Global LeaderCTD-ILD
621+1G->T
CFTR
Top PIs
Jacqueline M. KravekaMedical University of South Carolina4 years of reported clinical research
Studies Leukemia
Studies Tumors
33 reported clinical trials
83 drugs studied
Gregory Cote, MDMassachusetts General Hospital5 years of reported clinical research
Studies Sarcoma
Studies Solid Tumors
19 reported clinical trials
27 drugs studied
Michael Gold, MDOklahoma Cancer Specialists and Research Institute4 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
18 reported clinical trials
32 drugs studied
Mariam AlexanderMedical University of South Carolina3 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Studies Lung Cancer
15 reported clinical trials
25 drugs studied
Clinical Trials running at Medical University of South Carolina
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Cancer
Urothelial Carcinoma
Squamous Cell Carcinoma
Ovarian Tumors
Lymphoma
Multiple Myeloma
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting2 awards Phase 36 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Medical University of South Carolina?
Medical University of South Carolina is a medical facility located in Charleston, South Carolina. This center is recognized for care of Cancer, Fibrosis, Leukemia, Stroke, Tumors and other specialties. Medical University of South Carolina is involved with conducting 2,284 clinical trials across 1,783 conditions. There are 178 research doctors associated with this hospital, such as Jacqueline M. Kraveka, Gregory Cote, MD, Michael Gold, MD, and Mariam Alexander.
Where is Medical University of South Carolina located?
**Medical University of South Carolina (MUSC) Hospital**
- **Location:** 171 Ashley Ave, Charleston, SC 29425
- **Contact:** 843-792-1414
Who should I call to ask about financial aid or insurance network?
**Medical University of South Carolina (MUSC) Hospital Contact Information:**
- **General Inquiries:** Call 843-792-2300.
- **Financial Assistance:** Contact customer service at 843-792-2311 or 800-598-0624, Monday - Friday, 8 a.m. - 4:30 p.m.
- **Insurance Inquiries:**
- **Student Health Insurance Plan:** Administered through Blue Cross Blue Shield of South Carolina, call 1-855-844-3015.
- **Supplemental Retirement and Life Insurance:** Contact Sharon Goodmon-Brown at 843-345-0976.
- **Student Financial Aid:** Email finaid@musc.edu or use the Student Self-Service Portal to contact your assigned counselor.
What insurance does Medical University of South Carolina accept?
The Medical University of South Carolina (MUSC) accepts several insurance plans, including the MUSC Health Plan, a PPO with a network of hospitals, doctors, and service providers offering discounted fees. MUSC also provides a school-sponsored health insurance plan for students, administered by Academic HealthPlans (AHP) and underwritten by Blue Cross Blue Shield of South Carolina. Patients are encouraged to verify if their insurance covers MUSC Health services and to request inclusion in their network if not already covered.
At the University of South Carolina, all students must have health insurance. This includes undergraduates taking six or more hours and paying the student health fee, graduate students taking six hours or more, graduate students with assistantships, USC School of Medicine students enrolled in one or more hours, and all international students. The Student Health Insurance Plan is the only in-network plan at Student Health, and waiving the University Sponsored health insurance plan may result in out-of-network costs for some services at Student Health.
What awards or recognition has Medical University of South Carolina received?
The Medical University of South Carolina (MUSC) hospital, located in Charleston, South Carolina, is celebrated for its pioneering biomedical research and clinical trials, led by a team of internationally recognized faculty and scientists. MUSC has been recognized for its leadership in Inclusive Excellence, notably receiving the Earl B. Higgins Award. The institution is dedicated to transforming medical treatments and advancing medical understanding through the collaborative efforts of its scientists and physicians.